The National Institutes of Health (NIH) is offering a funding opportunity titled "NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)" aimed at supporting investigator-initiated Phase I clinical trials for heart, lung, blood, and sleep (HLBS) disorders. Applicants are expected to initiate their clinical trials within the first quarter of the project period, with a focus on developing therapeutic and diagnostic interventions, and must provide a detailed project management plan that includes milestones for trial completion and participant enrollment. This grant, identified as PAR-24-172, allows for direct costs up to $1.515 million per year and may extend for a duration of up to three years, promoting inclusivity in clinical research by encouraging participation from underrepresented groups. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for January 7, 2027.